3.15
0.01 (0.32%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Opthea Limited | Bearish | Bearish |
Stockmoo Score
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Core |
Ownership
Name | Date | Shares Held |
---|---|---|
Regal Partners Ltd | 30 Jun 2024 | 2,907,403 |
Teacher Retirement System Of Texas | 30 Jun 2024 | 269,399 |
Stratos Wealth Partners, Ltd. | 30 Jun 2024 | 28,550 |
Frazier Financial Advisors, Llc | 30 Jun 2024 | 750 |
52 Weeks Range | ||
Median | 12.00 (280.95%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 03 Sep 2024 | 12.00 (280.95%) | Buy | 2.91 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |